See more : Central Energy Partners LP (ENGY) Income Statement Analysis – Financial Results
Complete financial analysis of Zelira Therapeutics Limited (ZLDAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zelira Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Globetronics Technology Bhd. (7022.KL) Income Statement Analysis – Financial Results
- Huntington Bancshares Incorporated (HBANL) Income Statement Analysis – Financial Results
- Zapf Creation AG (ZAPNF) Income Statement Analysis – Financial Results
- ViewCast.com, Inc. (VCST) Income Statement Analysis – Financial Results
- Marudai Food Co., Ltd. (2288.T) Income Statement Analysis – Financial Results
Zelira Therapeutics Limited (ZLDAF)
About Zelira Therapeutics Limited
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.95K | 301.12K | 1.54M | 663.32K | 0.00 | 769.03K | 313.76K | 100.04K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 0.00 | 21.08M | 140.69K | 569.48K | 501.04K |
| Cost of Revenue | 84.67K | 3.52M | 939.05K | 228.22K | 275.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.85M | 70.66K | 178.19K | 141.29K |
| Gross Profit | 10.28K | -3.22M | 601.57K | 435.09K | -275.05K | 769.03K | 313.76K | 100.04K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 0.00 | 24.93M | 70.03K | 391.29K | 359.75K |
| Gross Profit Ratio | 10.83% | -1,068.03% | 39.05% | 65.59% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 118.25% | 49.78% | 68.71% | 71.80% |
| Research & Development | 2.81M | 1.34M | 1.40M | 2.08M | 3.69M | 2.33M | 1.79M | 668.41K | 14.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.34M | 3.06M | 6.08M | 4.49M | 1.97M | 1.25M | 397.37K | 1.35M | 456.94K | 207.75K | 180.00K | 214.56K | 443.35K | 242.51K | 490.56K | 507.34K | 59.75K | 1.20M | 675.35K | 372.46K | 245.36K |
| Selling & Marketing | 0.00 | -468.36K | 715.24K | 510.07K | 0.00 | 0.00 | 0.00 | 1.05M | 63.25K | 83.84K | 67.65K | 84.80K | 123.57K | 126.28K | 490.52K | 365.25K | 187.33K | 333.39K | 62.53K | 46.07K | 60.51K |
| SG&A | 1.34M | 2.59M | 6.08M | 4.49M | 1.97M | 1.25M | 397.37K | 1.35M | 456.94K | 207.75K | 180.00K | 214.56K | 443.35K | 242.51K | 490.56K | 507.34K | 59.75K | 1.20M | 675.35K | 372.46K | 245.36K |
| Other Expenses | -4.14M | -266.52K | 1.28M | 1.25M | 925.49K | 580.44K | 959.82K | 99.34K | -24.95K | 12.16K | -15.78K | -18.92K | -36.03K | 440.67K | -201.19K | 177.42K | -211.08K | -1.51M | -99.53K | 45.46K | 522.50K |
| Operating Expenses | 10.28K | 4.20M | 14.25M | 10.20M | 7.94M | 4.24M | 2.83M | 6.32M | 876.42K | 423.83K | 295.18K | 322.06K | 630.63K | 463.08K | 1.15M | 1.85M | 487.99K | 46.55M | 1.35M | 860.64K | 1.04M |
| Cost & Expenses | 5.50M | 7.71M | 15.19M | 10.42M | 7.94M | 4.24M | 2.83M | 6.32M | 876.42K | 423.83K | 295.18K | 322.06K | 630.63K | 463.08K | 1.15M | 1.85M | 487.99K | 42.70M | 1.42M | 1.04M | 1.18M |
| Interest Income | 309.00 | 134.00 | 10.60K | 723.00 | 8.60K | 90.14K | 138.57K | 67.72K | 2.73K | 11.59K | 20.74K | 29.13K | 28.70K | 29.44K | 58.77K | 129.43K | 22.62K | 64.67K | 95.38K | 117.06K | 129.78K |
| Interest Expense | 739.27K | 76.66K | 53.85K | 42.63K | 12.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 102.20K | 203.13K | 4.83K | 16.00 |
| Depreciation & Amortization | 479.04K | 545.22K | 588.54K | 474.26K | 275.05K | 3.32M | 2.37M | 2.44M | 161.10K | 0.00 | 336.00 | 5.22K | 13.95K | 11.54K | 16.97K | 16.81K | 0.00 | 3.15M | 62.05K | 72.28K | 27.02K |
| EBITDA | -35.52M | -5.65M | -11.77M | -8.03M | -7.51M | 0.00 | 0.00 | 0.00 | 0.00 | -423.83K | -294.84K | -316.84K | -616.67K | -451.54K | -1.10M | -1.53M | -487.99K | -19.94M | -1.22M | -234.56K | 1.45K |
| EBITDA Ratio | -37,409.90% | -2,280.68% | -764.05% | -1,210.92% | 0.00% | -551.13% | -901.40% | -6,321.81% | -292.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,955.02% | 0.00% | 0.00% | -94.60% | -867.45% | -41.19% | 0.29% |
| Operating Income | -5.94M | -7.41M | -12.36M | -8.51M | -7.00M | -4.24M | -2.83M | -6.32M | -876.42K | -423.83K | -295.18K | -322.06K | -630.63K | -463.08K | -686.56K | -1.55M | -487.99K | -23.09M | -1.28M | -306.84K | -25.56K |
| Operating Income Ratio | -6,253.93% | -2,461.74% | -802.25% | -1,282.41% | 0.00% | -551.13% | -901.40% | -6,321.81% | -292.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,004.55% | 0.00% | 0.00% | -109.55% | -911.55% | -53.88% | -5.10% |
| Total Other Income/Expenses | -30.80M | 233.40K | -26.27K | 248.29K | 352.62K | -262.65K | 622.83K | -3.75M | -108.21K | 23.75K | 4.96K | 10.22K | -7.33K | 470.11K | -1.00M | -18.72M | 22.62K | -16.54M | -203.13K | -4.83K | 652.26K |
| Income Before Tax | -36.74M | -7.41M | -12.41M | -8.55M | -7.02M | -3.57M | -1.73M | -6.16M | -898.64K | -400.08K | -290.22K | -311.84K | -637.96K | 7.03K | -1.69M | -20.27M | -465.37K | -38.16M | -1.49M | -311.67K | -25.58K |
| Income Before Tax Ratio | -38,692.98% | -2,461.31% | -805.75% | -1,288.84% | 0.00% | -463.94% | -551.32% | -6,154.83% | -299.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,928.45% | 0.00% | 0.00% | -181.04% | -1,055.93% | -54.73% | -5.10% |
| Income Tax Expense | 0.00 | -1.14M | 860.83K | 1.30M | 937.84K | -769.03K | -313.76K | -100.04K | -163.83K | 0.00 | -20.74K | -29.13K | -28.70K | -29.44K | 370.74K | 211.67K | -13.08M | -1.41M | -584.27K | -311.67K | -25.58K |
| Net Income | -36.57M | -5.57M | -11.95M | -8.55M | -7.02M | -3.57M | -1.73M | -6.16M | -898.64K | -400.08K | -290.22K | -311.84K | -637.96K | 7.03K | -1.69M | -20.27M | 12.61M | -38.16M | -901.34K | -311.67K | 0.00 |
| Net Income Ratio | -38,513.04% | -1,850.75% | -775.35% | -1,288.84% | 0.00% | -463.94% | -551.32% | -6,154.83% | -299.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,928.45% | 0.00% | 0.00% | -181.04% | -640.65% | -54.73% | 0.00% |
| EPS | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | -0.83 | -0.40 | -2.18 | -1.39 | -0.73 | -0.53 | -0.57 | -1.99 | 0.02 | -5.03 | -116.56 | 464.49 | -15.47K | -543.30 | -255.26 | 0.00 |
| EPS Diluted | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | -0.83 | -0.40 | -2.18 | -1.39 | -0.73 | -0.53 | -0.57 | -1.99 | 0.02 | -5.03 | -116.56 | 464.49 | -15.47K | -543.30 | -240.67 | 0.00 |
| Weighted Avg Shares Out | 11.35M | 10.07M | 8.04M | 6.63M | 4.85M | 4.31M | 4.31M | 2.83M | 646.55K | 551.24K | 551.24K | 551.24K | 320.42K | 335.85K | 335.86K | 173.91K | 27.16K | 2.47K | 1.66K | 1.22K | 1.09K |
| Weighted Avg Shares Out (Dil) | 11.35M | 10.07M | 8.04M | 6.63M | 4.85M | 4.31M | 4.31M | 2.83M | 646.55K | 551.24K | 551.24K | 551.24K | 320.42K | 335.85K | 335.86K | 173.91K | 27.16K | 2.47K | 1.66K | 1.30K | 1.09K |
Zelira Therapeutics launches HOPE™ range of autism spectrum disorder products in Washington DC
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has launched its HOPE™ range of autism spectrum disorder products in Washington DC through its partnership with Alternative Solutions LLC, a licensed manufacturer and distributor of medical cannabis products. Washington DC has reciprocity with 32...
Zelira Therapeutics well-placed to build on considerable March quarter momentum
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) is well placed to build on the considerable momentum generated during the March quarter by launching new products and expanding into new geographies, according to managing director Dr Oludare Odumosu. With a suite of new products...
Zelira Therapeutics delivers record March quarter revenue of $225,000
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) achieved record product sales and licensing revenues of A$225,000 during the March quarter - up 249% on the prior six months. This revenue growth demonstrates the start of the company's commercialisation ramp-up, with growth driven largely...
Zelira Therapeutics well-placed to capitalise on expanding global medicinal cannabis sector
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has strategically consolidated its operations to transfer the leadership of the company to its US-based team, with Dr Oludare Odumosu to assume the role of global managing director. With the successful launch of multiple...
Zelira Therapeutics positions for future growth with transition to US-based leadership team led by Dr Oludare Odumosu
Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) strategic consolidation of its operations will see leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the role of global managing director. Dr Richard Hopkins has decided to step...
Zelira Therapeutics appointed to the board of US National Cannabis Roundtable
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has been appointed to the board of directors of the National Cannabis Roundtable (NCR) in Washington DC, US. The company will be represented on the NCR board by its US chief executive officer Oludare...
Source: https://incomestatements.info
Category: Stock Reports